Home » Topics » Regulatory » EMA

EMA
RSS

CHMP recommends marketing authorization for Pfizer's Fablyn in osteoporosis

Dec. 29, 2008

Oncoscience withdraws Theraloc (nimotuzumab) marketing authorization application

Dec. 5, 2008

Further explanation of CHMP's negative opinion for Santhera's Sovrima for Friedreich's ataxia

Nov. 25, 2008

EMEA recommends temporary suspension of Acomplia marketing authorization in obese patients

Oct. 24, 2008

EMEA withdraws marketing authorization for Protopy in the European Union

Oct. 9, 2008

CHMP recommends variations to marketing authorization of Cancidas

Sep. 30, 2008

CHMP recommends marketing authorization for Azarga in open-angle glaucoma

Sep. 30, 2008

GSK withdraws European MAA for Quintanrix vaccine

Sep. 3, 2008

EMEA presents an update on reports of PML in MS patients treated with Tysabri

Aug. 14, 2008

CHMP recommends marketing authorization for GSK's prepandemic influenza vaccine

July 30, 2008

Popular Stories

Today's news in brief
BioWorld
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
New mechanism of action identified for QC-6352
BioWorld Science
QC-6352 is a small molecule developed to inhibit the histone demethylase 4 (KDM4) that has shown potent antitumoral activity and which has a derivative named...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...